Topical Peptide Composition for Multiple Sclerosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis do not effectively decrease the rate of progression of the disease after treatment cessation, and existing compositions do not address the long-term reduction of autoreactive lymphocyte activity or neurological impairment.
Innovation Solution
A pharmaceutical composition comprising MBP, MOG, and PLP peptides, administered topically, which induces immunotolerance and reduces autoreactive lymphocyte activity, thereby decreasing the progression of multiple sclerosis even after treatment cessation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a single antigen (GPMBP) is used for treatment, then the treatment approach is simple, but the long-term effectiveness and sustained immunotolerance are insufficient
Solution Approach 1:
The patent uses a composite antigen composition containing four different myelin-derived peptides (MBP 88-102, MOG 34-54, PLP 139-152, and MBP 21-31) instead of a single antigen. This composite approach targets multiple epitopes recognized by autoreactive T cells, creating more comprehensive and sustained immunotolerance. The combination of different peptides from various myelin proteins provides broader immune coverage and prevents escape from immune regulation, thereby improving long-term treatment effectiveness while maintaining a relatively simple topical application format.
2Duration of action of stationary object
If conventional treatments are used, then the treatment protocol is established, but the rate of disease progression is not decreased after treatment cessation
Solution Approach 1:
The patent employs preliminary immunomodulatory action through topical application of myelin peptides before significant disease progression occurs. The treatment induces immunotolerance and modulates the immune response in advance, creating a protective effect that persists after treatment cessation. This preliminary action establishes a state of immune regulation that continues to control disease progression even after the treatment period ends, addressing the critical gap in conventional therapies where effectiveness diminishes after treatment stops.
3Ease of operation
If topical administration is used, then the treatment is non-invasive and easy to apply, but the ability to induce sustained immunotolerance and reduce progression rate is insufficient
Solution Approach 1:
The patent utilizes parameter changes in the form of a transdermal delivery system that modifies the physical and chemical parameters of peptide administration. By controlling the release rate, concentration gradient, and contact time of the peptide composition through the skin, the treatment achieves sufficient systemic absorption to induce immunotolerance. This parameter optimization allows the non-invasive topical route to deliver therapeutically effective doses that sustain immunomodulation and reduce disease progression rate over the long term.
Data Source
AI summary
The subject of the present invention is pharmaceutical composition containing active ingredients in the form of a peptide of the myelin basic protein, a peptide from the myelin protein and oligodendrocytes as well as a peptide of the proteolipid protein as well as the use of the composition in the manufacturing of a drug for topical administration in the treatment of the disease multiple sclerosis. The composition may be administered topically.